Intelligence for people who need to know what changed before everyone else.

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

ROBIN Trial to Explore RT Effects on Immune System in Rectal Cancer

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

SillaJen initiates Phase 1 trial of BAL0891 in advanced solid tumors and AML

NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

Nemtabrutinib Study vs Ibrutinib/Acalabrutinib in 1L CLL/SLL Initiated

Zilovertamab Vedotin Shows Promise in rrDLBCL with Standard Care in Phase 2/3 Study

Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark

Trial on S-ICD Implantation Without Defibrillation Testing Shows Non-Inferiority

R-MVST Cells Show Promise for Treating Refractory Viral Infections

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

FDA Approves Supplement for INQOVI (NDA 212576) by Taiho Oncology

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

Study on PSB Pacing to Prevent Atrial Fibrillation in Sinus Node Dysfunction Patients

Boomerang Medical initiates pivotal trial for device in ulcerative colitis

Phase 3 Trial of TQB2868 and Anlotinib in Metastatic Pancreatic Cancer Initiated

DB-1303/BNT323 Trial in HER2-Low Metastatic Breast Cancer Initiated

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

Phase 2 Study of AUR103 Calcium in Advanced Neuroendocrine Tumours Initiated

KSHB002 Trial Shows Equivalence to ORENCIA in PK, Safety, and Immunogenicity for RA

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

Study on Socio-aesthetics Care Impact on Cancer Patients' Quality of Life

Launch of Alzheimer's Disease Neuroimaging Initiative 4 to Validate Biomarkers

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

Phase 3 Trial of GammaTile vs Standard Care in GBM Surgery Initiated

Phase 3 Study of L606 in Patients with PH-ILD Shows Safety and Efficacy Potential

Phase III Trial Compares 6 vs. 12 Months of HER2-Targeted Therapy in Breast Cancer

Phase 3 Trial of Orelabrutinib in Secondary Progressive MS Underway

Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer

Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched

Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer

Ifinatamab Deruxtecan Receives Priority Review for ES-SCLC in the U.S.

Analysis Reveals Key Trends in ALS Immunotherapeutics Research and Collaboration Gaps

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer

Phase III Trial of Hemay005 in Chinese Patients with Ulcerative Colitis Initiated

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis

Phase III Trial of SYHA1813 Shows Promise for High-Grade Meningiomas

Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway

Merck's Acquisition of Terns Pharmaceuticals Advances as HSR Waiting Period Expires

Trial Evaluates Pelvic Radiotherapy with ADT in Node Positive Prostate Cancer

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

FDA Approves Merck’s IDVYNSO for Virologically Suppressed HIV-1 Patients

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study

Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics

mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

Phase III Trial Evaluates Triapine with Cisplatin for Advanced Cervical and Vaginal Cancers

Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

NeoAdjuvant Therapy Trial for TNBC: Sacituzumab Govitecan + Pembrolizumab

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

Merck Acquires Terns Pharmaceuticals, Enhancing Oncology Pipeline with TERN-701

Merck Receives FDA Approval for IDVYNSO, Expands Oncology Pipeline and Animal Health Sales

Roche Presents New Data on Vabysmo and Susvimo at ARVO 2026

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

FDA Approves Tzield for Pediatric Patients with Stage 3 Type 1 Diabetes

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

AstraZeneca Reports Strong Q1 2026 Revenue Growth and Positive NME Readouts

Merck Acknowledges Daiichi Sankyo's ADC Manufacturing Update

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

Lilly expands infectious disease portfolio with three strategic acquisitions

Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women

FDA approves Lilly's EBGLYSS® for atopic dermatitis with unique dosing regimen

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

Saphnelo Self-Administration Approved in the US for SLE Treatment

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

European Commission Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment

FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Lilly's Foundayo shows superior A1C reduction and weight loss in pivotal diabetes trials

Truqap approved in US for PTEN-deficient metastatic prostate cancer

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer

Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

Enhertu Gains FDA Approval for Two New HER2+ Early Breast Cancer Indications

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

Foundayo shows significant weight reduction in older adults with obesity in new analysis

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

Merck's Sacituzumab Tirumotecan Shows OS and PFS Improvement in Endometrial Cancer Phase 3 Trial

Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies

Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies

Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations

Ultomiris meets primary endpoint in Phase III trial for IgAN

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC

Non-coding RNAs as regulators of aerobic glycolysis in pancreatic ductal adenocarcinoma

Nanomaterial-based vaccines show promise for improved rotavirus protection

Novel CD2-targeted bispecific antibody enhances T cell engagers for solid tumors

Phase 3 Trial of Maridebart Cafraglutide in Obstructive Sleep Apnea Patients

Phase 3 Study of Duvakitug for Moderately to Severely Active Ulcerative Colitis Initiated

Lilly's Zepbound® (tirzepatide) targets moderate obstructive sleep apnea in national campaign with Shaquille O'Neal

Phase III Trial of TR115 vs Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis

GSK's AS03-adjuvanted H5N8 vaccine shows promising immunogenicity and safety in Phase 1/2 trial

Rivaroxaban Trial for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients

New Biobank Established for Cutaneous Melanoma and Non-Melanoma Research

Study on Ultrasound Guidance for Central Catheterization in Obese ICU Patients

COVAC-2 Vaccine Shows Safety and Immunogenicity as COVID-19 Booster in Phase 1 Trial

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

Phase II Trial of SAL0140 Shows Promise for Primary Aldosteronism

Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic

Trial on MRI-guided SBRT for Liver Metastases Aims to Establish Safe Dose Levels

Phase 3 Study of CU-20101 Shows Promise for Glabellar Lines Compared to Botox

MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated

Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma

Trial Compares Silicone Barrier Spray to Zinc Oxide for Incontinence-Associated Dermatitis

Dapagliflozin vs Metformin for Antipsychotic-Induced Weight Gain in Clinical Trial

Clinical Trial Evaluates PRS CK STORM for Cytokine Storm in Respiratory Infections

4CMenB and MenACWY-CRM Vaccines Co-Administered Safely in Adolescents

Study on Timing of Midazolam in Pediatric Adenotonsillectomy to Assess Stress and Recovery

Trial of CXD and Ketogenic Diet for MASLD Shows Structured Approach

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

Trial Comparing Behavioral Activation to Relapse Prevention for Veterans with AUD and PTSD

FDA Clears Bridge Device for Opioid Use Disorder Treatment; Efficacy Under Evaluation

Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated

Study on Image-Guided Cancer Treatments Using Spectral Angio-CT

AI-Driven Nutrition Study for Type 2 Diabetes Shows Promise for Glycemic Control

Pridopidine Phase 3 Trial Initiated for ALS Efficacy and Safety Evaluation

LIPUS and microbubbles enhance amphotericin B delivery for cryptococcal meningitis therapy

Study Compares PE Therapy, Pharmacotherapy, and Combination for PTSD in Veterans

Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma

FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

FDA Accepts Supplement for SPRAVATO (Esketamine Hydrochloride)

FDA Accepts Supplement Application for Artesunate by Amivas

FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE

FDA Grants Approval for Pimozide ANDA219897 by Novitium Pharma

FDA Grants Approval for Olmesartan Medoxomil and Hydrochlorothiazide ANDA206371

FDA Accepts Supplemental Application for Concerta by Janssen

FDA Grants AP Status for Lidocaine Hydrochloride 0.4% in Dextrose 5%

FDA Approval Status Update for Lidocaine Hydrochloride 0.4% in Dextrose 5%

FDA Grants AP Status for Diltiazem Hydrochloride ANDA216327

FDA Approval Process Update for Mycophenolate Mofetil by Strides Pharma

FDA Approves Supplement for Methylprednisolone Acetate by Sandoz

Sandoz's Methylprednisolone ANDA040194 Receives AP Status from FDA

Glenmark Pharmaceuticals submits supplemental application for Lamotrigine

FDA Grants AP Status for Doxycycline Hyclate Supplement by Impax Labs

Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial

South African HCPs Support Dual Prevention Pill but Highlight Key Challenges

FDA Grants AP Status for MESNA ANDA203364 Submission by RISING

FDA Accepts Supplement for VABYSMO by Genentech

FDA Approval Status Update for Losartan Potassium by Micro Labs

Alembic's Duloxetine Hydrochloride Supplement Receives AP Status from FDA

FDA Approves Deflazacort Supplement Application by Upsher Smith Labs

Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status

FDA Approves Supplement for Levetiracetam by Chartwell RX

FDA Accepts Application for COSOPT PF Supplement by THEA PHARMA

FDA Grants Approval for Phenylephrine Hydrochloride by Baxter Healthcare

FDA Submission Update for Ondansetron Hydrochloride (ANDA078127)

FDA Accepts Supplement Application for Tyvaso (Treprostinil)

FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma

Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction

Pilot Study on Geniculate Artery Embolization for Knee Osteoarthritis Initiated

Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial

Efzimfotase alfa shows positive Phase III results in hypophosphatasia

Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes

TAPUR Study Evaluates Targeted Therapies in Advanced Cancer with Genomic Variants

Tozorakimab achieves primary endpoints in Phase III trials for COPD

Enhertu recommended for EU approval in HER2+ metastatic solid tumours

Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema

Study on NMES for Functional Recovery in COPD and Pneumonia Patients

FDA Issues Guidance on Postapproval Pregnancy Safety Studies

AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment

Breztri Gains US Approval as First Triple Therapy for Asthma